Effects of Rosiglitazone on Expressions of Plasminogen Activator Inhibitor-1 in Kidney of Streptozotocin-diabetic Rats

Objective To investigate the role of rosiglitazone in improving blood lipids and proteinuria in rats with Type 2 diabete,and the effect of rosiglitazone on expressions of plasminogen activator inhibitor-1 in kidney of streptozotocin-diabetic rats.Methods The rats were randomly assigned to following groups: normal control(CON)group,diabetic rat(DM) group,rosiglitazone 2 mg/(kg·d) treatment group(DM+R).The levels of urinary protein,total cholesterol,triglyceride and renal function change in rats were measured after10 weeks.The mRNA levels of cortical PAI-1were detected by RT-PCR.The protein expressions of PAI-1in the rat kidney tissues were detected by immunohistochemistry.Results As compared to CON group,the serum sugar,triglyceride,and the urinary protein excretion in DM group increased.The levels of blood sugar,and microalbuminuria decreased significantly after the rosiglitazone treatment.In comparison with normal group,the expression of PAI-1 in diabetic rat markedly increased(P0.05).In comparison with diabetic rat group,rosiglitazone could significantly decrease the expression of PAI-1 (P0.05).Conclusion Rosiglitazone has better effects in improving the blood sugar and proteinuria of streptozotocin-diabetic rats.The expression of renal cortical PAI-1 is down-regulated by rosiglitazone.